Clinical Outcomes of Radiofrequency Ablation Combined with Transarterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Non-hepatocellular Carcinoma Malignant Liver Tumors.

Autor:	Yoshihara T; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan.; Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Japan., Hasegawa T; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Sato Y; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Yamaura H; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Murata S; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Chatani S; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Tsukii R; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Nagasawa K; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan., Tsushima Y; Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Japan., Inaba Y; Department of Diagnostic and Interventional Radiology, Aichi Cancer Center, Japan.
Jazyk:	angličtina
Zdroj:	Interventional radiology (Higashimatsuyama-shi (Japan) [Interv Radiol (Higashimatsuyama)] 2023 Mar 01; Vol. 8 (1), pp. 7-13. Date of Electronic Publication: 2023 Mar 01 (Print Publication: 2023).
DOI:	10.22575/interventionalradiology.2022-0017
Abstrakt:	Purpose: To retrospectively evaluate the outcomes of radiofrequency ablation combined with transarterial chemoembolization using degradable starch microspheres for non-hepatocellular carcinoma malignant liver tumors. Material and Methods: A total of 15 patients (13 men, 2 women; median age, 67 years) who underwent radiofrequency ablation immediately after transarterial chemoembolization using degradable starch microspheres for liver tumors between July 2011 and September 2020 were included in this study. Thirteen patients had liver metastases from colorectal cancer (n = 6), esophageal cancer (n = 2), lung cancer (n = 2), and other tumors (n = 3), and 2 patients had primary liver tumor of cholangiocellular carcinoma (n = 1) and gastrinoma (n = 1). Twenty tumors (median size, 16 mm) were treated in 17 sessions. Technical success, safety, local tumor progression, and overall survival were evaluated. Safety was assessed according to the clinical practice guideline of the Society of Interventional Radiology. Results: All treatment procedures were successfully completed. There were no major complications. Grade-B complications of self-limiting pneumothorax (n = 1), vomiting (n = 1), and fever (n = 1) occurred in 1 session each. Local tumor progression developed in two tumors (local tumor progression rate, 10%, 2/20). The local tumor progression rates were 5% and 11% at 1 year and at 3 and 5 years, respectively. Tumor size of more than 20 mm ( P = 0.0003) and contact with major vessels ( P = 0.03) were significant risk factors for local tumor progression. The patients were treated with repeat radiofrequency ablation combined with transarterial chemoembolization using degradable starch microspheres. During median follow-up of 48 months (range, 4-77 months), 5 patients died (33%, 5/15). The overall survival rates were 100%, 85%, and 57% at 1, 3, and 5 years, respectively. The median overall survival time was 69 months. Conclusions: Radiofrequency ablation combined with transarterial chemoembolization using degradable starch microspheres was safe and showed favorable local control for non-hepatocellular carcinoma malignant liver tumors. Competing Interests: none (© 2023 Japanese Society of Interventional Radiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu